Sandbox/table: Difference between revisions
< Sandbox
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
{| style="border: 2px solid #DCDCDC; font-size: 90%; width: 80%;" | {| style="border: 2px solid #DCDCDC; font-size: 90%; width: 80%;" | ||
|+ Countries with a reported prevalence <15% of ''H. pylori'' resistance to clarithromycin | |+ '''Countries with a reported prevalence <15% of ''H. pylori'' resistance to clarithromycin''' | ||
! style="background: #DCDCDC;" | Europe | ! style="background: #DCDCDC;" | Europe | ||
! style="background: #DCDCDC;" | North America | ! style="background: #DCDCDC;" | North America | ||
Line 19: | Line 19: | ||
* UK (3.9–4.4%) | * UK (3.9–4.4%) | ||
| style="background: #F5F5F5; padding: 0 10px; width: 20%;" valign=top | | | style="background: #F5F5F5; padding: 0 10px; width: 20%;" valign=top | | ||
* USA (10.6–12.2%) | * USA (10.6–12.2%)<sup>†</sup> | ||
| style="background: #F5F5F5; padding: 0 10px; width: 20%;" valign=top | | | style="background: #F5F5F5; padding: 0 10px; width: 20%;" valign=top | | ||
* Brazil (9.8%) | * Brazil (9.8%) | ||
Line 30: | Line 30: | ||
* New Zealand (6.8%) | * New Zealand (6.8%) | ||
|} | |} | ||
<SMALL><sup>†</sup> There is a reported prevalence of 15% in the Northeast of the US.</SMALL> |
Revision as of 15:18, 6 June 2014
Europe | North America | South America | Middle East | Far East |
---|---|---|---|---|
|
|
|
|
|
† There is a reported prevalence of 15% in the Northeast of the US.